{"abstracts-retrieval-response": {
    "item": {
        "ait:process-info": {
            "ait:status": {
                "@state": "update",
                "@type": "core",
                "@stage": "S300"
            },
            "ait:date-delivered": {
                "@day": "14",
                "@timestamp": "2023-07-14T01:52:29.000029-04:00",
                "@year": "2023",
                "@month": "07"
            },
            "ait:date-sort": {
                "@day": "01",
                "@year": "2019",
                "@month": "11"
            }
        },
        "xocs:meta": {"xocs:funding-list": {
            "@pui-match": "primary",
            "@has-funding-info": "1",
            "xocs:funding": {
                "xocs:funding-agency-matched-string": "Gilead",
                "xocs:funding-agency": "Gilead Sciences",
                "xocs:funding-agency-id": "http://data.elsevier.com/vocabulary/SciValFunders/100005564",
                "xocs:funding-agency-country": "http://sws.geonames.org/6252001/"
            },
            "xocs:funding-addon-generated-timestamp": "2021-05-25T19:32:19.806Z",
            "xocs:funding-text": "This study was sponsored by Gilead Sciences, Inc. (Gilead). The authors thank the patients who participated in this trial and their families, the principal investigators (appendix pages 1\u20133) and their staff, the Gilead study staff, and Anna Kido (Gilead employee) for providing editorial assistance.",
            "xocs:funding-addon-type": "http://vtw.elsevier.com/data/voc/AddOnTypes/50.7/aggregated-refined"
        }},
        "bibrecord": {
            "head": {
                "author-group": [
                    {
                        "affiliation": {
                            "country": "Uganda",
                            "@afid": "60071691",
                            "@country": "uga",
                            "city": "Kampala",
                            "organization": {"$": "Joint Clinical Research Centre"},
                            "affiliation-id": {"@afid": "60071691"},
                            "ce:source-text": "Joint Clinical Research Centre Kampala Uganda"
                        },
                        "author": [{
                            "ce:given-name": "Cissy",
                            "preferred-name": {
                                "ce:given-name": "Cissy",
                                "ce:initials": "C.",
                                "ce:surname": "Kityo",
                                "ce:indexed-name": "Kityo C."
                            },
                            "@seq": "1",
                            "ce:initials": "C.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:degrees": "MD",
                            "ce:surname": "Kityo",
                            "@auid": "6602918610",
                            "ce:indexed-name": "Kityo C."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "United States",
                            "@afid": "113700425",
                            "@country": "usa",
                            "city": "Savannah",
                            "organization": [
                                {"$": "Georgia Department of Public Health"},
                                {"$": "Coastal Health District"},
                                {"$": "Chatham Care Center"}
                            ],
                            "affiliation-id": {
                                "@afid": "113700425",
                                "@dptid": "121265228"
                            },
                            "state": "GA",
                            "ce:source-text": "Georgia Department of Public Health Coastal Health District Chatham CARE Center Savannah GA",
                            "@dptid": "121265228"
                        },
                        "author": [{
                            "ce:given-name": "Debbie",
                            "preferred-name": {
                                "ce:given-name": "Debbie",
                                "ce:initials": "D.",
                                "ce:surname": "Hagins",
                                "ce:indexed-name": "Hagins D."
                            },
                            "@seq": "2",
                            "ce:initials": "D.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:degrees": "MD",
                            "ce:surname": "Hagins",
                            "@auid": "36522862600",
                            "ce:indexed-name": "Hagins D."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "Dominican Republic",
                            "@afid": "105310604",
                            "@country": "dom",
                            "city": "Santo Domingo",
                            "organization": [
                                {"$": "Zona Universitaria"},
                                {"$": "Instituto Dominicano de Estudios Virológicos"}
                            ],
                            "affiliation-id": {
                                "@afid": "105310604",
                                "@dptid": "123886674"
                            },
                            "ce:source-text": "Zona Universitaria Instituto Dominicano de Estudios Virológicos Santo Domingo Dominion Republic Canada",
                            "@dptid": "123886674"
                        },
                        "author": [{
                            "ce:given-name": "Ellen",
                            "preferred-name": {
                                "ce:given-name": "Ellen",
                                "ce:initials": "E.",
                                "ce:surname": "Koenig",
                                "ce:indexed-name": "Koenig E."
                            },
                            "@seq": "3",
                            "ce:initials": "E.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:degrees": "MD",
                            "ce:surname": "Koenig",
                            "@auid": "7005320371",
                            "ce:indexed-name": "Koenig E."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "Thailand",
                            "@afid": "60028190",
                            "@country": "tha",
                            "city": "Bangkok",
                            "organization": [
                                {"$": "HIV-NAT"},
                                {"$": "Thai Red Cross Aids Research Centre and Faculty of Medicine"},
                                {"$": "Chulalongkorn University"}
                            ],
                            "affiliation-id": [
                                {"@afid": "60028190"},
                                {"@afid": "60031780"},
                                {"@afid": "60016965"}
                            ],
                            "ce:source-text": "HIV-NAT Thai Red Cross AIDS Research Centre and Faculty of Medicine Chulalongkorn University Bangkok Thailand"
                        },
                        "author": [{
                            "ce:given-name": "Anchalee",
                            "preferred-name": {
                                "ce:given-name": "Anchalee",
                                "ce:initials": "A.",
                                "ce:surname": "Avihingsanon",
                                "ce:indexed-name": "Avihingsanon A."
                            },
                            "@seq": "4",
                            "ce:initials": "A.",
                            "@date-locked": "2023-01-18T05:16:58.450",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:degrees": "MD",
                            "ce:surname": "Avihingsanon",
                            "@auid": "57196347321",
                            "ce:indexed-name": "Avihingsanon A."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "Thailand",
                            "@afid": "60017165",
                            "@country": "tha",
                            "city": "Khon Kaen",
                            "organization": {"$": "Khon Kaen University"},
                            "affiliation-id": {"@afid": "60017165"},
                            "ce:source-text": "Khon Kaen University Khon Kaen Thailand"
                        },
                        "author": [{
                            "ce:given-name": "Ploenchan",
                            "preferred-name": {
                                "ce:given-name": "Ploenchan",
                                "ce:initials": "P.",
                                "ce:surname": "Chetchotisakd",
                                "ce:indexed-name": "Chetchotisakd P."
                            },
                            "@seq": "5",
                            "ce:initials": "P.",
                            "@date-locked": "2021-10-29T02:35:24.871",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:degrees": "MD",
                            "ce:surname": "Chetchotisakd",
                            "@auid": "56992885200",
                            "ce:indexed-name": "Chetchotisakd P."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "Thailand",
                            "@afid": "60000881",
                            "@country": "tha",
                            "city": "Chiang Mai",
                            "organization": {"$": "Chiang Mai University"},
                            "affiliation-id": {"@afid": "60000881"},
                            "ce:source-text": "Chiang Mai University Chiang Mai Thailand"
                        },
                        "author": [{
                            "ce:given-name": "Khuanchai",
                            "preferred-name": {
                                "ce:given-name": "Khuanchai",
                                "ce:initials": "K.",
                                "ce:surname": "Supparatpinyo",
                                "ce:indexed-name": "Supparatpinyo K."
                            },
                            "@seq": "6",
                            "ce:initials": "K.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:degrees": "MD",
                            "ce:surname": "Supparatpinyo",
                            "@auid": "6602542079",
                            "ce:indexed-name": "Supparatpinyo K."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "Russian Federation",
                            "@afid": "115403233",
                            "@country": "rus",
                            "city": "Krasnoyarsk",
                            "organization": {"$": "Krasnoyarsk Territorial Center for Prevention and Control of Aids and Infectious Diseases"},
                            "affiliation-id": {"@afid": "115403233"},
                            "ce:source-text": "Krasnoyarsk Territorial Center for Prevention and Control of AIDS and Infectious Diseases Krasnoyarsk Russia"
                        },
                        "author": [{
                            "ce:given-name": "Natalya",
                            "preferred-name": {
                                "ce:given-name": "Natalya",
                                "ce:initials": "N.",
                                "ce:surname": "Gankina",
                                "ce:indexed-name": "Gankina N."
                            },
                            "@seq": "7",
                            "ce:initials": "N.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:degrees": "MD",
                            "ce:surname": "Gankina",
                            "@auid": "57197827501",
                            "ce:indexed-name": "Gankina N."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "Russian Federation",
                            "@afid": "108398532",
                            "@country": "rus",
                            "city": "Moscow",
                            "organization": {"$": "Center for Prevention and Control of Aids"},
                            "affiliation-id": {"@afid": "108398532"},
                            "ce:source-text": "Center for Prevention and Control of AIDS Moscow Russia"
                        },
                        "author": [{
                            "ce:given-name": "Vadim",
                            "preferred-name": {
                                "ce:given-name": "Vadim",
                                "ce:initials": "V.",
                                "ce:surname": "Pokrovsky",
                                "ce:indexed-name": "Pokrovsky V."
                            },
                            "@seq": "8",
                            "ce:initials": "V.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:degrees": "MD",
                            "ce:surname": "Pokrovsky",
                            "@auid": "57215123636",
                            "ce:indexed-name": "Pokrovsky V."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "Russian Federation",
                            "@afid": "60069625",
                            "@country": "rus",
                            "city": "Saint-Petersburg",
                            "organization": {"$": "Fed. Budgetary Inst. republican Clin. Infect. Hosp. of the Min. of Health of the Russian Federation"},
                            "affiliation-id": {"@afid": "60069625"},
                            "ce:source-text": "Federal Budgetary Institution \"Republican Clinical Infectious Hospital\" of the Ministry of Health of the Russian Federation Saint-Petersburg Russia"
                        },
                        "author": [{
                            "ce:given-name": "Evgeny",
                            "preferred-name": {
                                "ce:given-name": "Evgeny",
                                "ce:initials": "E.",
                                "ce:surname": "Voronin",
                                "ce:indexed-name": "Voronin E."
                            },
                            "@seq": "9",
                            "ce:initials": "E.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:degrees": "MD",
                            "ce:surname": "Voronin",
                            "@auid": "7005899830",
                            "ce:indexed-name": "Voronin E."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "United States",
                            "@afid": "60026005",
                            "@country": "usa",
                            "city": "Macon",
                            "organization": {"$": "Mercer University School of Medicine"},
                            "affiliation-id": {"@afid": "60026005"},
                            "state": "GA",
                            "ce:source-text": "Mercer University School of Medicine Macon GA"
                        },
                        "author": [{
                            "ce:given-name": "Jeffrey L.",
                            "preferred-name": {
                                "ce:given-name": "Jeffrey L.",
                                "ce:initials": "J.L.",
                                "ce:surname": "Stephens",
                                "ce:indexed-name": "Stephens J.L."
                            },
                            "@seq": "10",
                            "ce:initials": "J.L.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:degrees": "MD",
                            "ce:surname": "Stephens",
                            "@auid": "57210456228",
                            "ce:indexed-name": "Stephens J.L."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "United States",
                            "@afid": "100429817",
                            "@country": "usa",
                            "city": "Orlando",
                            "organization": {"$": "Orlando Immunology Center"},
                            "affiliation-id": {"@afid": "100429817"},
                            "state": "FL",
                            "ce:source-text": "Orlando Immunology Center Orlando FL; and"
                        },
                        "author": [{
                            "ce:given-name": "Edwin",
                            "preferred-name": {
                                "ce:given-name": "Edwin",
                                "ce:initials": "E.",
                                "ce:surname": "Dejesus",
                                "ce:indexed-name": "Dejesus E."
                            },
                            "@seq": "11",
                            "ce:initials": "E.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:degrees": "MD",
                            "ce:surname": "Dejesus",
                            "@auid": "55549526100",
                            "ce:indexed-name": "Dejesus E."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "United States",
                            "@afid": "60002909",
                            "@country": "usa",
                            "city": "Foster City",
                            "organization": {"$": "Gilead Sciences Inc."},
                            "affiliation-id": {"@afid": "60002909"},
                            "state": "CA",
                            "ce:source-text": "Gilead Sciences Inc. Foster City CA."
                        },
                        "author": [
                            {
                                "ce:given-name": "Hui",
                                "preferred-name": {
                                    "ce:given-name": "Hui",
                                    "ce:initials": "H.",
                                    "ce:surname": "Wang",
                                    "ce:indexed-name": "Wang H."
                                },
                                "@seq": "12",
                                "ce:initials": "H.",
                                "@_fa": "true",
                                "@type": "auth",
                                "ce:degrees": "PhD",
                                "ce:surname": "Wang",
                                "@auid": "57196428615",
                                "ce:indexed-name": "Wang H."
                            },
                            {
                                "ce:given-name": "Rima K.",
                                "preferred-name": {
                                    "ce:given-name": "Rima K.",
                                    "ce:initials": "R.K.",
                                    "ce:surname": "Acosta",
                                    "ce:indexed-name": "Acosta R.K."
                                },
                                "@seq": "13",
                                "ce:initials": "R.K.",
                                "@_fa": "true",
                                "@type": "auth",
                                "ce:degrees": "BS",
                                "ce:surname": "Acosta",
                                "@auid": "57205221636",
                                "ce:indexed-name": "Acosta R.K."
                            },
                            {
                                "ce:given-name": "Huyen",
                                "preferred-name": {
                                    "ce:given-name": "Huyen",
                                    "ce:initials": "H.",
                                    "ce:surname": "Cao",
                                    "ce:indexed-name": "Cao H."
                                },
                                "@seq": "14",
                                "ce:initials": "H.",
                                "@_fa": "true",
                                "@type": "auth",
                                "ce:degrees": "MD",
                                "ce:surname": "Cao",
                                "@auid": "56471119200",
                                "ce:indexed-name": "Cao H."
                            },
                            {
                                "ce:given-name": "Erin",
                                "preferred-name": {
                                    "ce:given-name": "Erin",
                                    "ce:initials": "E.",
                                    "ce:surname": "Quirk",
                                    "ce:indexed-name": "Quirk E."
                                },
                                "@seq": "15",
                                "ce:initials": "E.",
                                "@_fa": "true",
                                "@type": "auth",
                                "ce:degrees": "MD",
                                "ce:surname": "Quirk",
                                "@auid": "24282056300",
                                "ce:indexed-name": "Quirk E."
                            },
                            {
                                "ce:given-name": "Hal",
                                "preferred-name": {
                                    "ce:given-name": "Hal",
                                    "ce:initials": "H.",
                                    "ce:surname": "Martin",
                                    "ce:indexed-name": "Martin H."
                                },
                                "@seq": "16",
                                "ce:initials": "H.",
                                "@_fa": "true",
                                "@type": "auth",
                                "ce:degrees": "MD",
                                "ce:surname": "Martin",
                                "@auid": "56173399700",
                                "ce:indexed-name": "Martin H."
                            },
                            {
                                "ce:given-name": "Tariro",
                                "preferred-name": {
                                    "ce:given-name": "Tariro",
                                    "ce:initials": "T.",
                                    "ce:surname": "Makadzange",
                                    "ce:indexed-name": "Makadzange T."
                                },
                                "@seq": "17",
                                "ce:initials": "T.",
                                "@_fa": "true",
                                "@type": "auth",
                                "ce:degrees": "MD, PhD",
                                "ce:surname": "Makadzange",
                                "@auid": "6506062019",
                                "ce:indexed-name": "Makadzange T."
                            }
                        ]
                    }
                ],
                "citation-title": "Switching to Fixed-Dose Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed HIV-1 Infected Women: A Randomized, Open-Label, Multicenter, Active-Controlled, Phase 3, Noninferiority Trial",
                "abstracts": "© 2019 Wolters Kluwer Health, Inc. All rights reserved.Background:Bictegravir, coformulated with emtricitabine/tenofovir alafenamide as a fixed-dose combination (B/F/TAF), is recommended for treatment of HIV-1-infection. Multiple studies of B/F/TAF in treatment-naive and virologically suppressed cohorts have shown high efficacy and tolerability with no treatment-emergent resistance through 48 weeks. Participants in these studies have been predominantly men. We report 48-week results from a phase 3 study evaluating switching to B/F/TAF, specifically in a globally distributed trial population of women.Methods:In this multicenter, randomized, open-label, active-controlled, noninferiority trial (ClinicalTrials.gov NCT02652624), women living with HIV who were virologically suppressed (HIV-1 RNA levels <50 copies/mL) on a regimen containing either TAF or tenofovir disoproxil fumarate were randomly assigned (1:1) to switch to B/F/TAF (50/200/25 mg) or stay on baseline regimen (SBR) once daily for 48 weeks. Primary endpoint was proportion of participants with plasma HIV-1 RNA ≥50 copies/mL at week 48 (U.S. Food and Drug Administration snapshot algorithm); prespecified noninferiority margin was 4%.Findings:We randomized 472 participants and treated 470 (234 B/F/TAF, 236 SBR). Switching to B/F/TAF was noninferior to SBR for the primary outcome, as 1.7% (4/234) vs 1.7% (4/236) had HIV-1 RNA ≥50 copies/mL at week 48 (difference 0.0%, 95.001% confidence interval: -2.9% to 2.9%). No individual receiving B/F/TAF developed treatment-emergent resistance. Both treatments were well-tolerated; no participant discontinued treatment because of an adverse event.Interpretation:Fixed-dose combination B/F/TAF provides a safe and efficacious option for ongoing treatment of HIV in women. This study contributes important data on safety, tolerability, and outcomes of antiretroviral therapy among women living with HIV.",
                "correspondence": {
                    "affiliation": {
                        "country": "United States",
                        "address-part": "333 Lakeside Drive",
                        "postal-code": "94404",
                        "@country": "usa",
                        "city": "Foster City",
                        "organization": [
                            {"$": "Gilead Sciences"},
                            {"$": "Inc."}
                        ],
                        "state": "CA",
                        "ce:source-text": "Correspondence to: Tariro Makadzange, MD, PhD, Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404"
                    },
                    "person": {
                        "ce:given-name": "Tariro",
                        "ce:initials": "T.",
                        "ce:degrees": "MD, PhD",
                        "ce:surname": "Makadzange",
                        "ce:indexed-name": "Makadzange T."
                    }
                },
                "citation-info": {
                    "author-keywords": {"author-keyword": [
                        {
                            "$": "bictegravir",
                            "@xml:lang": "eng"
                        },
                        {
                            "$": "HIV",
                            "@xml:lang": "eng"
                        },
                        {
                            "$": "INSTI",
                            "@xml:lang": "eng"
                        },
                        {
                            "$": "tenofovir alafenamide",
                            "@xml:lang": "eng"
                        },
                        {
                            "$": "women",
                            "@xml:lang": "eng"
                        }
                    ]},
                    "citation-type": {"@code": "ar"},
                    "citation-language": {
                        "@language": "English",
                        "@xml:lang": "eng"
                    },
                    "abstract-language": {
                        "@language": "English",
                        "@xml:lang": "eng"
                    }
                },
                "source": {
                    "website": {"ce:e-address": {
                        "$": "http://journals.lww.com/jaids/pages/default.aspx",
                        "@type": "email"
                    }},
                    "translated-sourcetitle": {
                        "$": "Journal of Acquired Immune Deficiency Syndromes",
                        "@xml:lang": "eng"
                    },
                    "volisspag": {
                        "voliss": {
                            "@volume": "82",
                            "@issue": "3"
                        },
                        "pagerange": {
                            "@first": "321",
                            "@last": "328"
                        }
                    },
                    "@type": "j",
                    "sourcetitle": "Journal of Acquired Immune Deficiency Syndromes",
                    "publicationdate": {
                        "month": "11",
                        "year": "2019",
                        "date-text": {
                            "@xfab-added": "true",
                            "$": "1 November 2019"
                        },
                        "day": "01"
                    },
                    "codencode": "JJASF",
                    "sourcetitle-abbrev": "J. Acquired Immune Defic. Syndr.",
                    "@country": "usa",
                    "issn": [
                        {
                            "$": "10779450",
                            "@type": "electronic"
                        },
                        {
                            "$": "15254135",
                            "@type": "print"
                        }
                    ],
                    "publicationyear": {"@first": "2019"},
                    "publisher": {
                        "publishername": "Lippincott Williams and Wilkins",
                        "ce:e-address": {
                            "$": "kathiest.clai@apta.org",
                            "@type": "email"
                        }
                    },
                    "@srcid": "15300154823"
                },
                "enhancement": {
                    "classificationgroup": {"classifications": [
                        {
                            "@type": "CABSCLASS",
                            "classification": {
                                "classification-code": "99",
                                "classification-description": "General"
                            }
                        },
                        {
                            "@type": "EMCLASS",
                            "classification": [
                                {
                                    "classification-code": "26",
                                    "classification-description": "Immunology, Serology and Transplantation"
                                },
                                {
                                    "classification-code": "37",
                                    "classification-description": "Drug Literature Index"
                                }
                            ]
                        },
                        {
                            "@type": "ASJC",
                            "classification": [
                                {"$": "2725"},
                                {"$": "2736"}
                            ]
                        },
                        {
                            "@type": "SUBJABBR",
                            "classification": "MEDI"
                        }
                    ]},
                    "chemicalgroup": {"chemicals": [
                        {
                            "@source": "esbd",
                            "chemical": [
                                {
                                    "cas-registry-number": [
                                        {"$": "1611493-60-7"},
                                        {"$": "1807988-02-8"}
                                    ],
                                    "chemical-name": "bictegravir"
                                },
                                {
                                    "cas-registry-number": "57-88-5",
                                    "chemical-name": "cholesterol"
                                },
                                {
                                    "cas-registry-number": [
                                        {"$": "19230-81-0"},
                                        {"$": "60-27-5"}
                                    ],
                                    "chemical-name": "creatinine"
                                },
                                {
                                    "cas-registry-number": [
                                        {"$": "137530-41-7"},
                                        {"$": "143491-54-7"},
                                        {"$": "143491-57-0"}
                                    ],
                                    "chemical-name": "emtricitabine"
                                },
                                {
                                    "cas-registry-number": [
                                        {"$": "379270-37-8"},
                                        {"$": "1392275-56-7"}
                                    ],
                                    "chemical-name": "tenofovir alafenamide"
                                },
                                {
                                    "cas-registry-number": "202138-50-9",
                                    "chemical-name": "tenofovir disoproxil"
                                },
                                {
                                    "cas-registry-number": [
                                        {"$": "22177-51-1"},
                                        {"$": "2922-28-3"},
                                        {"$": "73-24-5"}
                                    ],
                                    "chemical-name": "adenine"
                                },
                                {
                                    "cas-registry-number": [
                                        {"$": "147127-19-3"},
                                        {"$": "147127-20-6"}
                                    ],
                                    "chemical-name": "tenofovir"
                                }
                            ]
                        },
                        {
                            "@source": "nlm",
                            "chemical": [
                                {"chemical-name": "Adenine"},
                                {"chemical-name": "Anti-HIV Agents"},
                                {"chemical-name": "bictegravir"},
                                {"chemical-name": "Emtricitabine"},
                                {"chemical-name": "emtricitabine tenofovir alafenamide"},
                                {"chemical-name": "GS-7340"},
                                {"chemical-name": "Heterocyclic Compounds, 4 or More Rings"},
                                {"chemical-name": "Tenofovir"}
                            ]
                        }
                    ]}
                }
            },
            "item-info": {
                "copyright": {
                    "$": "Copyright 2020 Elsevier B.V., All rights reserved.",
                    "@type": "Elsevier"
                },
                "external-source": "In-Data-Review",
                "dbcollection": [
                    {"$": "CABS"},
                    {"$": "EMBASE"},
                    {"$": "MEDL"},
                    {"$": "REAXYSCAR"},
                    {"$": "SCOPUS"},
                    {"$": "Scopusbase"}
                ],
                "history": {"date-created": {
                    "@day": "25",
                    "@timestamp": "BST 03:55:18",
                    "@year": "2020",
                    "@month": "02"
                }},
                "itemidlist": {
                    "itemid": [
                        {
                            "$": "630931767",
                            "@idtype": "PUI"
                        },
                        {
                            "$": "629588192",
                            "@idtype": "associatedPUI"
                        },
                        {
                            "$": "2020053111",
                            "@idtype": "CABS"
                        },
                        {
                            "$": "924176116",
                            "@idtype": "CAR-ID"
                        },
                        {
                            "$": "20200128925",
                            "@idtype": "EMBASE"
                        },
                        {
                            "$": "31609930",
                            "@idtype": "MEDL"
                        },
                        {
                            "$": "20200355500",
                            "@idtype": "REAXYSCAR"
                        },
                        {
                            "$": "20200501333",
                            "@idtype": "SCOPUS"
                        },
                        {
                            "$": "85073178758",
                            "@idtype": "SCP"
                        },
                        {
                            "$": "85073178758",
                            "@idtype": "SGR"
                        },
                        {
                            "$": "629588192",
                            "@idtype": "PUIsecondary"
                        },
                        {
                            "$": "77780299",
                            "@idtype": "OSIN"
                        }
                    ],
                    "ce:doi": "10.1097/QAI.0000000000002137"
                }
            },
            "tail": {"bibliography": {
                "@refcount": "32",
                "reference": [
                    {
                        "ref-fulltext": "UNAIDS. Fact Sheet-World AIDS Day 2017. Available at: www.unaids.org/sites/default/files/media-asset/UNAIDS-FactSheet-en.pdf. Accessed May 30, 2018.",
                        "@id": "1",
                        "ref-info": {
                            "ref-website": {"ce:e-address": {
                                "$": "www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_en.pdf",
                                "@type": "email"
                            }},
                            "refd-itemidlist": {"itemid": {
                                "$": "85042444262",
                                "@idtype": "SGR"
                            }},
                            "ref-text": "Accessed May 30, 2018",
                            "ref-authors": {"collaboration": {
                                "@seq": "1",
                                "ce:text": "UNAIDS",
                                "ce:indexed-name": "UNAIDS"
                            }},
                            "ref-sourcetitle": "Fact Sheet-World Aids Day 2017"
                        },
                        "ce:source-text": "UNAIDS. Fact Sheet-World AIDS Day 2017. Available at: www.unaids.org/sites/default/files/media-asset/UNAIDS-FactSheet-en.pdf. Accessed May 30, 2018."
                    },
                    {
                        "ref-fulltext": "Liu KA, Dipietro Mager NA,. Women's involvement in clinical trials: historical perspective and future implications. Pharm Pract (Granada). 2016; 14: 708.",
                        "@id": "2",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2016"},
                            "ref-title": {"ref-titletext": "Women's involvement in clinical trials: Historical perspective and future implications"},
                            "refd-itemidlist": {"itemid": {
                                "$": "84960463456",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "14"},
                                "pagerange": {"@first": "708"}
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "K.A.",
                                    "@_fa": "true",
                                    "ce:surname": "Liu",
                                    "ce:indexed-name": "Liu K.A."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "N.A.",
                                    "@_fa": "true",
                                    "ce:surname": "Dipietro Mager",
                                    "ce:indexed-name": "Dipietro Mager N.A."
                                }
                            ]},
                            "ref-sourcetitle": "Pharm Pract (Granada)."
                        },
                        "ce:source-text": "Liu KA, Dipietro Mager NA,. Women's involvement in clinical trials: historical perspective and future implications. Pharm Pract (Granada). 2016; 14: 708."
                    },
                    {
                        "ref-fulltext": "Curno MJ, Rossi S, Hodges-Mameletzis I, et al. A systematic review of the inclusion (or exclusion) of women in HIV research: from clinical studies of antiretrovirals and vaccines to cure strategies. J Acquir Immune Defic Syndr. 2016; 71: 181-188.",
                        "@id": "3",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2016"},
                            "ref-title": {"ref-titletext": "A systematic review of the inclusion (or exclusion) of women in HIV research: From clinical studies of antiretrovirals and vaccines to cure strategies"},
                            "refd-itemidlist": {"itemid": {
                                "$": "84955678258",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "71"},
                                "pagerange": {
                                    "@first": "181",
                                    "@last": "188"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M.J.",
                                        "@_fa": "true",
                                        "ce:surname": "Curno",
                                        "ce:indexed-name": "Curno M.J."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Rossi",
                                        "ce:indexed-name": "Rossi S."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "I.",
                                        "@_fa": "true",
                                        "ce:surname": "Hodges-Mameletzis",
                                        "ce:indexed-name": "Hodges-Mameletzis I."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Acquir Immune Defic Syndr."
                        },
                        "ce:source-text": "Curno MJ, Rossi S, Hodges-Mameletzis I, et al. A systematic review of the inclusion (or exclusion) of women in HIV research: from clinical studies of antiretrovirals and vaccines to cure strategies. J Acquir Immune Defic Syndr. 2016; 71: 181-188."
                    },
                    {
                        "ref-fulltext": "Gandhi M, Bacchetti P, Miotti P, et al. Does patient sex affect human immunodeficiency virus levels? Clin Infect Dis. 2002; 35: 313-322.",
                        "@id": "4",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2002"},
                            "ref-title": {"ref-titletext": "Does patient sex affect human immunodeficiency virus levels?"},
                            "refd-itemidlist": {"itemid": {
                                "$": "0036680356",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "35"},
                                "pagerange": {
                                    "@first": "313",
                                    "@last": "322"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Gandhi",
                                        "ce:indexed-name": "Gandhi M."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "P.",
                                        "@_fa": "true",
                                        "ce:surname": "Bacchetti",
                                        "ce:indexed-name": "Bacchetti P."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "P.",
                                        "@_fa": "true",
                                        "ce:surname": "Miotti",
                                        "ce:indexed-name": "Miotti P."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Clin Infect Dis."
                        },
                        "ce:source-text": "Gandhi M, Bacchetti P, Miotti P, et al. Does patient sex affect human immunodeficiency virus levels? Clin Infect Dis. 2002; 35: 313-322."
                    },
                    {
                        "ref-fulltext": "Maskew M, Brennan AT, Westreich D, et al. Gender differences in mortality and CD4 count response among virally suppressed HIV-positive patients. J Womens Health (Larchmt). 2013; 22: 113-120.",
                        "@id": "5",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2013"},
                            "ref-title": {"ref-titletext": "Gender differences in mortality and CD4 count response among virally suppressed HIV-positive patients"},
                            "refd-itemidlist": {"itemid": {
                                "$": "84873632715",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "22"},
                                "pagerange": {
                                    "@first": "113",
                                    "@last": "120"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Maskew",
                                        "ce:indexed-name": "Maskew M."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "A.T.",
                                        "@_fa": "true",
                                        "ce:surname": "Brennan",
                                        "ce:indexed-name": "Brennan A.T."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "D.",
                                        "@_fa": "true",
                                        "ce:surname": "Westreich",
                                        "ce:indexed-name": "Westreich D."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Womens Health (Larchmt)."
                        },
                        "ce:source-text": "Maskew M, Brennan AT, Westreich D, et al. Gender differences in mortality and CD4 count response among virally suppressed HIV-positive patients. J Womens Health (Larchmt). 2013; 22: 113-120."
                    },
                    {
                        "ref-fulltext": "Anderson GD,. Gender differences in pharmacological response. Int Rev Neurobiol. 2008; 83: 1-10.",
                        "@id": "6",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2008"},
                            "ref-title": {"ref-titletext": "Gender differences in pharmacological response"},
                            "refd-itemidlist": {"itemid": {
                                "$": "53249086413",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "83"},
                                "pagerange": {
                                    "@first": "1",
                                    "@last": "10"
                                }
                            },
                            "ref-authors": {"author": [{
                                "@seq": "1",
                                "ce:initials": "G.D.",
                                "@_fa": "true",
                                "ce:surname": "Anderson",
                                "ce:indexed-name": "Anderson G.D."
                            }]},
                            "ref-sourcetitle": "Int Rev Neurobiol."
                        },
                        "ce:source-text": "Anderson GD,. Gender differences in pharmacological response. Int Rev Neurobiol. 2008; 83: 1-10."
                    },
                    {
                        "ref-fulltext": "Soldin OP, Mattison DR,. Sex differences in pharmacokinetics and pharmacodynamics. Clin Pharmacokinet. 2009; 48: 143-157.",
                        "@id": "7",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2009"},
                            "ref-title": {"ref-titletext": "Sex differences in pharmacokinetics and pharmacodynamics"},
                            "refd-itemidlist": {"itemid": {
                                "$": "65349137639",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "48"},
                                "pagerange": {
                                    "@first": "143",
                                    "@last": "157"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "O.P.",
                                    "@_fa": "true",
                                    "ce:surname": "Soldin",
                                    "ce:indexed-name": "Soldin O.P."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "D.R.",
                                    "@_fa": "true",
                                    "ce:surname": "Mattison",
                                    "ce:indexed-name": "Mattison D.R."
                                }
                            ]},
                            "ref-sourcetitle": "Clin Pharmacokinet."
                        },
                        "ce:source-text": "Soldin OP, Mattison DR,. Sex differences in pharmacokinetics and pharmacodynamics. Clin Pharmacokinet. 2009; 48: 143-157."
                    },
                    {
                        "ref-fulltext": "Günthard HF, Saag MS, Benson CA, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the International Antiviral Society-USA Panel. JAMA. 2016; 316: 191-210.",
                        "@id": "8",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2016"},
                            "ref-title": {"ref-titletext": "Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the International Antiviral Society-USA Panel"},
                            "refd-itemidlist": {"itemid": {
                                "$": "84978371920",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "316"},
                                "pagerange": {
                                    "@first": "191",
                                    "@last": "210"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "H.F.",
                                        "@_fa": "true",
                                        "ce:surname": "Günthard",
                                        "ce:indexed-name": "Gunthard H.F."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M.S.",
                                        "@_fa": "true",
                                        "ce:surname": "Saag",
                                        "ce:indexed-name": "Saag M.S."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "C.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Benson",
                                        "ce:indexed-name": "Benson C.A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "JAMA."
                        },
                        "ce:source-text": "Günthard HF, Saag MS, Benson CA, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the International Antiviral Society-USA Panel. JAMA. 2016; 316: 191-210."
                    },
                    {
                        "ref-fulltext": "European AIDS Clinical Society. Guidelines. Version 9.0. 2017. Brussels, Belgium: European AIDS Clinical Society. Available at: www.eacsociety.org/files/guidelines-9.0-english.pdf. Accessed May 30, 2018.",
                        "@id": "9",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-website": {"ce:e-address": {
                                "$": "www.eacsociety.org/files/guidelines_9.0-english.pdf",
                                "@type": "email"
                            }},
                            "refd-itemidlist": {"itemid": {
                                "$": "85044392547",
                                "@idtype": "SGR"
                            }},
                            "ref-text": "Brussels, Belgium: European AIDS Clinical Society. Accessed May 30, 2018",
                            "ref-authors": {"collaboration": {
                                "@seq": "1",
                                "ce:text": "European AIDS Clinical Society",
                                "ce:indexed-name": "European AIDS Clinical Society"
                            }},
                            "ref-sourcetitle": "Guidelines. Version 9.0"
                        },
                        "ce:source-text": "European AIDS Clinical Society. Guidelines. Version 9.0. 2017. Brussels, Belgium: European AIDS Clinical Society. Available at: www.eacsociety.org/files/guidelines-9.0-english.pdf. Accessed May 30, 2018."
                    },
                    {
                        "ref-fulltext": "Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Washington, DC: U. S. Department of Health and Human Services; 2018. Available at: https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. Accessed May 30, 2018.",
                        "@id": "10",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf",
                                "@type": "email"
                            }},
                            "refd-itemidlist": {"itemid": {
                                "$": "1442349426",
                                "@idtype": "SGR"
                            }},
                            "ref-text": "Washington, DC: U. S. Department of Health and Human Services; Accessed May 30, 2018",
                            "ref-authors": {"collaboration": {
                                "@seq": "1",
                                "ce:text": "Panel on Antiretroviral Guidelines for Adults and Adolescents",
                                "ce:indexed-name": "Panel on Antiretroviral Guidelines for Adults and Adolescents"
                            }},
                            "ref-sourcetitle": "Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents"
                        },
                        "ce:source-text": "Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Washington, DC: U. S. Department of Health and Human Services; 2018. Available at: https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. Accessed May 30, 2018."
                    },
                    {
                        "ref-fulltext": "Gallant JE, Thompson M, DeJesus E, et al. Antiviral activity, safety, and pharmacokinetics of bictegravir as 10-day monotherapy in HIV-1-infected adults. J Acquir Immune Defic Syndr. 2017; 75: 61-66.",
                        "@id": "11",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-title": {"ref-titletext": "Antiviral activity, safety, and pharmacokinetics of bictegravir as 10-day monotherapy in HIV-1-infected adults"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85012892233",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "75"},
                                "pagerange": {
                                    "@first": "61",
                                    "@last": "66"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "J.E.",
                                        "@_fa": "true",
                                        "ce:surname": "Gallant",
                                        "ce:indexed-name": "Gallant J.E."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Thompson",
                                        "ce:indexed-name": "Thompson M."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "E.",
                                        "@_fa": "true",
                                        "ce:surname": "DeJesus",
                                        "ce:indexed-name": "DeJesus E."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Acquir Immune Defic Syndr."
                        },
                        "ce:source-text": "Gallant JE, Thompson M, DeJesus E, et al. Antiviral activity, safety, and pharmacokinetics of bictegravir as 10-day monotherapy in HIV-1-infected adults. J Acquir Immune Defic Syndr. 2017; 75: 61-66."
                    },
                    {
                        "ref-fulltext": "Tsiang M, Jones GS, Goldsmith J, et al. Antiviral activity of bictegravir (GS-9883), a novel potent HIV-1 integrase strand transfer inhibitor with an improved resistance profile. Antimicrob Agents Chemother. 2016; 60: 7086-7097.",
                        "@id": "12",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2016"},
                            "ref-title": {"ref-titletext": "Antiviral activity of bictegravir (GS-9883), a novel potent HIV-1 integrase strand transfer inhibitor with an improved resistance profile"},
                            "refd-itemidlist": {"itemid": {
                                "$": "84996488595",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "60"},
                                "pagerange": {
                                    "@first": "7086",
                                    "@last": "7097"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Tsiang",
                                        "ce:indexed-name": "Tsiang M."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "G.S.",
                                        "@_fa": "true",
                                        "ce:surname": "Jones",
                                        "ce:indexed-name": "Jones G.S."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Goldsmith",
                                        "ce:indexed-name": "Goldsmith J."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Antimicrob Agents Chemother."
                        },
                        "ce:source-text": "Tsiang M, Jones GS, Goldsmith J, et al. Antiviral activity of bictegravir (GS-9883), a novel potent HIV-1 integrase strand transfer inhibitor with an improved resistance profile. Antimicrob Agents Chemother. 2016; 60: 7086-7097."
                    },
                    {
                        "ref-fulltext": "Custodio J, Ma G, SenGupta D, et al. Lack of pharmacokinetic and pharmacodynamic interactions between the integrase strand transfer inhibitor bictegravir and the oral contraceptive ethinyl estradiol/norgestimate. HIV Med. 2018; 19: s21-s152.",
                        "@id": "13",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Lack of pharmacokinetic and pharmacodynamic interactions between the integrase strand transfer inhibitor bictegravir and the oral contraceptive ethinyl estradiol/norgestimate"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85080848144",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "19"},
                                "pagerange": {
                                    "@first": "s21",
                                    "@last": "s152"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Custodio",
                                        "ce:indexed-name": "Custodio J."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "G.",
                                        "@_fa": "true",
                                        "ce:surname": "Ma",
                                        "ce:indexed-name": "Ma G."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "D.",
                                        "@_fa": "true",
                                        "ce:surname": "SenGupta",
                                        "ce:indexed-name": "SenGupta D."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Hiv Med."
                        },
                        "ce:source-text": "Custodio J, Ma G, SenGupta D, et al. Lack of pharmacokinetic and pharmacodynamic interactions between the integrase strand transfer inhibitor bictegravir and the oral contraceptive ethinyl estradiol/norgestimate. HIV Med. 2018; 19: s21-s152."
                    },
                    {
                        "ref-fulltext": "Gallant J, Lazzarin A, Mills A, et al. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. Lancet. 2017; 390: 2063-2072.",
                        "@id": "14",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-title": {"ref-titletext": "Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): A double-blind, multicentre, phase 3, randomised controlled non-inferiority trial"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85028623606",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "390"},
                                "pagerange": {
                                    "@first": "2063",
                                    "@last": "2072"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Gallant",
                                        "ce:indexed-name": "Gallant J."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Lazzarin",
                                        "ce:indexed-name": "Lazzarin A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Mills",
                                        "ce:indexed-name": "Mills A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet."
                        },
                        "ce:source-text": "Gallant J, Lazzarin A, Mills A, et al. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. Lancet. 2017; 390: 2063-2072."
                    },
                    {
                        "ref-fulltext": "Sax PE, Pozniak A, Montes ML, et al. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet. 2017; 390: 2073-2082.",
                        "@id": "15",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-title": {"ref-titletext": "Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): A randomised, double-blind, multicentre, phase 3, non-inferiority trial"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85028684793",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "390"},
                                "pagerange": {
                                    "@first": "2073",
                                    "@last": "2082"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "P.E.",
                                        "@_fa": "true",
                                        "ce:surname": "Sax",
                                        "ce:indexed-name": "Sax P.E."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Pozniak",
                                        "ce:indexed-name": "Pozniak A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M.L.",
                                        "@_fa": "true",
                                        "ce:surname": "Montes",
                                        "ce:indexed-name": "Montes M.L."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet."
                        },
                        "ce:source-text": "Sax PE, Pozniak A, Montes ML, et al. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet. 2017; 390: 2073-2082."
                    },
                    {
                        "ref-fulltext": "Molina JM, Ward DA, Brar I, et al. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed HIV-1 infected adults: a randomised, double-blinded, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet HIV. 2018; 5: e357-e365.",
                        "@id": "16",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed HIV-1 infected adults: A randomised, double-blinded, multicentre, active-controlled, phase 3, non-inferiority trial"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85048543569",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "5"},
                                "pagerange": {
                                    "@first": "e357",
                                    "@last": "e365"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "J.M.",
                                        "@_fa": "true",
                                        "ce:surname": "Molina",
                                        "ce:indexed-name": "Molina J.M."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "D.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Ward",
                                        "ce:indexed-name": "Ward D.A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "I.",
                                        "@_fa": "true",
                                        "ce:surname": "Brar",
                                        "ce:indexed-name": "Brar I."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet HIV."
                        },
                        "ce:source-text": "Molina JM, Ward DA, Brar I, et al. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed HIV-1 infected adults: a randomised, double-blinded, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet HIV. 2018; 5: e357-e365."
                    },
                    {
                        "ref-fulltext": "Daar ES, DeJesus E, Ruane P, et al. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed HIV-1 infected adults: a randomised, open-label, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet HIV. 2018; 5: e347-e356.",
                        "@id": "17",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed HIV-1 infected adults: A randomised, open-label, multicentre, active-controlled, phase 3, non-inferiority trial"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85048569792",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "5"},
                                "pagerange": {
                                    "@first": "e347",
                                    "@last": "e356"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "E.S.",
                                        "@_fa": "true",
                                        "ce:surname": "Daar",
                                        "ce:indexed-name": "Daar E.S."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "E.",
                                        "@_fa": "true",
                                        "ce:surname": "DeJesus",
                                        "ce:indexed-name": "DeJesus E."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "P.",
                                        "@_fa": "true",
                                        "ce:surname": "Ruane",
                                        "ce:indexed-name": "Ruane P."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet HIV."
                        },
                        "ce:source-text": "Daar ES, DeJesus E, Ruane P, et al. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed HIV-1 infected adults: a randomised, open-label, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet HIV. 2018; 5: e347-e356."
                    },
                    {
                        "ref-fulltext": "Wohl D, Clarke A, Maggiolo F, et al. Patient-reported symptoms over 48 Weeks among participants in randomized, double-blind, phase III non-inferiority trials of adults with HIV on Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus Co-formulated abacavir, dolutegravir, and lamivudine. Patient. 2018; 11: 561-573.",
                        "@id": "18",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Patient-reported symptoms over 48 Weeks among participants in randomized, double-blind, phase III non-inferiority trials of adults with HIV on Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus Co-formulated abacavir, dolutegravir, and lamivudine"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85049143882",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "11"},
                                "pagerange": {
                                    "@first": "561",
                                    "@last": "573"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "D.",
                                        "@_fa": "true",
                                        "ce:surname": "Wohl",
                                        "ce:indexed-name": "Wohl D."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Clarke",
                                        "ce:indexed-name": "Clarke A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "F.",
                                        "@_fa": "true",
                                        "ce:surname": "Maggiolo",
                                        "ce:indexed-name": "Maggiolo F."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Patient."
                        },
                        "ce:source-text": "Wohl D, Clarke A, Maggiolo F, et al. Patient-reported symptoms over 48 Weeks among participants in randomized, double-blind, phase III non-inferiority trials of adults with HIV on Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus Co-formulated abacavir, dolutegravir, and lamivudine. Patient. 2018; 11: 561-573."
                    },
                    {
                        "ref-fulltext": "Squires K, Kityo C, Hodder S, et al. Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study. Lancet HIV. 2016; 3: e410-e420.",
                        "@id": "19",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2016"},
                            "ref-title": {"ref-titletext": "Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): A randomised, controlled, double-blind, phase 3 study"},
                            "refd-itemidlist": {"itemid": {
                                "$": "84969972261",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "3"},
                                "pagerange": {
                                    "@first": "e410",
                                    "@last": "e420"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "K.",
                                        "@_fa": "true",
                                        "ce:surname": "Squires",
                                        "ce:indexed-name": "Squires K."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "C.",
                                        "@_fa": "true",
                                        "ce:surname": "Kityo",
                                        "ce:indexed-name": "Kityo C."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Hodder",
                                        "ce:indexed-name": "Hodder S."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet HIV."
                        },
                        "ce:source-text": "Squires K, Kityo C, Hodder S, et al. Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study. Lancet HIV. 2016; 3: e410-e420."
                    },
                    {
                        "ref-fulltext": "Mills A, Arribas JR, Andrade-Villanueva J, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study. Lancet Infect Dis. 2016; 16: 43-52.",
                        "@id": "20",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2016"},
                            "ref-title": {"ref-titletext": "Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: A randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85028245571",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "16"},
                                "pagerange": {
                                    "@first": "43",
                                    "@last": "52"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Mills",
                                        "ce:indexed-name": "Mills A."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "J.R.",
                                        "@_fa": "true",
                                        "ce:surname": "Arribas",
                                        "ce:indexed-name": "Arribas J.R."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Andrade-Villanueva",
                                        "ce:indexed-name": "Andrade-Villanueva J."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet Infect Dis."
                        },
                        "ce:source-text": "Mills A, Arribas JR, Andrade-Villanueva J, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study. Lancet Infect Dis. 2016; 16: 43-52."
                    },
                    {
                        "ref-fulltext": "Sax PE, Wohl D, Yin MT, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet. 2015; 385: 2606-2615.",
                        "@id": "21",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2015"},
                            "ref-title": {"ref-titletext": "Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: Two randomised, double-blind, phase 3, non-inferiority trials"},
                            "refd-itemidlist": {"itemid": {
                                "$": "84937215233",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "385"},
                                "pagerange": {
                                    "@first": "2606",
                                    "@last": "2615"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "P.E.",
                                        "@_fa": "true",
                                        "ce:surname": "Sax",
                                        "ce:indexed-name": "Sax P.E."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "D.",
                                        "@_fa": "true",
                                        "ce:surname": "Wohl",
                                        "ce:indexed-name": "Wohl D."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M.T.",
                                        "@_fa": "true",
                                        "ce:surname": "Yin",
                                        "ce:indexed-name": "Yin M.T."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet."
                        },
                        "ce:source-text": "Sax PE, Wohl D, Yin MT, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet. 2015; 385: 2606-2615."
                    },
                    {
                        "ref-fulltext": "Smith F, Hammerstorm T, Soon G, et al. A meta-analysis to assess the FDA DAVP's TLOVR algorithm in HIV submissions. Drug Inf J. 2011; 45: 291-300.",
                        "@id": "22",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2011"},
                            "ref-title": {"ref-titletext": "A meta-analysis to assess the FDA DAVP's TLOVR algorithm in HIV submissions"},
                            "refd-itemidlist": {"itemid": {
                                "$": "80051818332",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "45"},
                                "pagerange": {
                                    "@first": "291",
                                    "@last": "300"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "F.",
                                        "@_fa": "true",
                                        "ce:surname": "Smith",
                                        "ce:indexed-name": "Smith F."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "T.",
                                        "@_fa": "true",
                                        "ce:surname": "Hammerstorm",
                                        "ce:indexed-name": "Hammerstorm T."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "G.",
                                        "@_fa": "true",
                                        "ce:surname": "Soon",
                                        "ce:indexed-name": "Soon G."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Drug Inf J."
                        },
                        "ce:source-text": "Smith F, Hammerstorm T, Soon G, et al. A meta-analysis to assess the FDA DAVP's TLOVR algorithm in HIV submissions. Drug Inf J. 2011; 45: 291-300."
                    },
                    {
                        "ref-fulltext": "Trottier B, Lake JE, Logue K, et al. Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, Phase IIIb study. Antivir Ther. 2017; 22: 295-305.",
                        "@id": "23",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-title": {"ref-titletext": "Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): A 48-week, randomized, non-inferiority, open-label, Phase IIIb study"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85028662762",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "22"},
                                "pagerange": {
                                    "@first": "295",
                                    "@last": "305"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "B.",
                                        "@_fa": "true",
                                        "ce:surname": "Trottier",
                                        "ce:indexed-name": "Trottier B."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "J.E.",
                                        "@_fa": "true",
                                        "ce:surname": "Lake",
                                        "ce:indexed-name": "Lake J.E."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "K.",
                                        "@_fa": "true",
                                        "ce:surname": "Logue",
                                        "ce:indexed-name": "Logue K."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Antivir Ther."
                        },
                        "ce:source-text": "Trottier B, Lake JE, Logue K, et al. Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, Phase IIIb study. Antivir Ther. 2017; 22: 295-305."
                    },
                    {
                        "ref-fulltext": "Mocroft A, Kirk O, Reiss P, et al. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS. 2010; 24: 1667-1678.",
                        "@id": "24",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2010"},
                            "ref-title": {"ref-titletext": "Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients"},
                            "refd-itemidlist": {"itemid": {
                                "$": "77954349373",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "24"},
                                "pagerange": {
                                    "@first": "1667",
                                    "@last": "1678"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Mocroft",
                                        "ce:indexed-name": "Mocroft A."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "O.",
                                        "@_fa": "true",
                                        "ce:surname": "Kirk",
                                        "ce:indexed-name": "Kirk O."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "P.",
                                        "@_fa": "true",
                                        "ce:surname": "Reiss",
                                        "ce:indexed-name": "Reiss P."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "AIDS."
                        },
                        "ce:source-text": "Mocroft A, Kirk O, Reiss P, et al. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS. 2010; 24: 1667-1678."
                    },
                    {
                        "ref-fulltext": "Morlat P, Vivot A, Vandenhende MA, et al. Role of traditional risk factors and antiretroviral drugs in the incidence of chronic kidney disease, ANRS CO3 Aquitaine cohort, France. PLoS One. 2013; 8: e66223.",
                        "@id": "25",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2013"},
                            "ref-title": {"ref-titletext": "Role of traditional risk factors and antiretroviral drugs in the incidence of chronic kidney disease, ANRS CO3 Aquitaine cohort, France"},
                            "refd-itemidlist": {"itemid": {
                                "$": "84878936689",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "8"},
                                "pagerange": {"@first": "e66223"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "P.",
                                        "@_fa": "true",
                                        "ce:surname": "Morlat",
                                        "ce:indexed-name": "Morlat P."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Vivot",
                                        "ce:indexed-name": "Vivot A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Vandenhende",
                                        "ce:indexed-name": "Vandenhende M.A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "PLoS One."
                        },
                        "ce:source-text": "Morlat P, Vivot A, Vandenhende MA, et al. Role of traditional risk factors and antiretroviral drugs in the incidence of chronic kidney disease, ANRS CO3 Aquitaine cohort, France. PLoS One. 2013; 8: e66223."
                    },
                    {
                        "ref-fulltext": "Gallant JE, Daar ES, Raffi F, et al. Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial. Lancet HIV. 2016; 3: e158-e165.",
                        "@id": "26",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2016"},
                            "ref-title": {"ref-titletext": "Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: A randomised, double-blind, active-controlled phase 3 trial"},
                            "refd-itemidlist": {"itemid": {
                                "$": "84960824872",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "3"},
                                "pagerange": {
                                    "@first": "e158",
                                    "@last": "e165"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "J.E.",
                                        "@_fa": "true",
                                        "ce:surname": "Gallant",
                                        "ce:indexed-name": "Gallant J.E."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "E.S.",
                                        "@_fa": "true",
                                        "ce:surname": "Daar",
                                        "ce:indexed-name": "Daar E.S."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "F.",
                                        "@_fa": "true",
                                        "ce:surname": "Raffi",
                                        "ce:indexed-name": "Raffi F."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet HIV."
                        },
                        "ce:source-text": "Gallant JE, Daar ES, Raffi F, et al. Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial. Lancet HIV. 2016; 3: e158-e165."
                    },
                    {
                        "ref-fulltext": "Orkin C, DeJesus E, Ramgopal M, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study. Lancet HIV. 2017; 4: e195-e204.",
                        "@id": "27",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-title": {"ref-titletext": "Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: A randomised, double-blind, multicentre, phase 3b, non-inferiority study"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85014113739",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "4"},
                                "pagerange": {
                                    "@first": "e195",
                                    "@last": "e204"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "C.",
                                        "@_fa": "true",
                                        "ce:surname": "Orkin",
                                        "ce:indexed-name": "Orkin C."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "E.",
                                        "@_fa": "true",
                                        "ce:surname": "DeJesus",
                                        "ce:indexed-name": "DeJesus E."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Ramgopal",
                                        "ce:indexed-name": "Ramgopal M."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet HIV."
                        },
                        "ce:source-text": "Orkin C, DeJesus E, Ramgopal M, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study. Lancet HIV. 2017; 4: e195-e204."
                    },
                    {
                        "ref-fulltext": "DeJesus E, Ramgopal M, Crofoot G, et al. Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study. Lancet HIV. 2017; 4: e205-e213.",
                        "@id": "28",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-title": {"ref-titletext": "Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: A randomised, double-blind, multicentre, phase 3b, non-inferiority study"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85014064242",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "4"},
                                "pagerange": {
                                    "@first": "e205",
                                    "@last": "e213"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "E.",
                                        "@_fa": "true",
                                        "ce:surname": "DeJesus",
                                        "ce:indexed-name": "DeJesus E."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Ramgopal",
                                        "ce:indexed-name": "Ramgopal M."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "G.",
                                        "@_fa": "true",
                                        "ce:surname": "Crofoot",
                                        "ce:indexed-name": "Crofoot G."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet HIV."
                        },
                        "ce:source-text": "DeJesus E, Ramgopal M, Crofoot G, et al. Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study. Lancet HIV. 2017; 4: e205-e213."
                    },
                    {
                        "ref-fulltext": "Orrell C, Hagins DP, Belonosova E, et al. Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study. Lancet HIV. 2017; 4: e536-e546.",
                        "@id": "29",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-title": {"ref-titletext": "Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): Week 48 results from a randomised, open-label, non-inferiority, phase 3b study"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85024474883",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "4"},
                                "pagerange": {
                                    "@first": "e536",
                                    "@last": "e546"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "C.",
                                        "@_fa": "true",
                                        "ce:surname": "Orrell",
                                        "ce:indexed-name": "Orrell C."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "D.P.",
                                        "@_fa": "true",
                                        "ce:surname": "Hagins",
                                        "ce:indexed-name": "Hagins D.P."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "E.",
                                        "@_fa": "true",
                                        "ce:surname": "Belonosova",
                                        "ce:indexed-name": "Belonosova E."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet HIV."
                        },
                        "ce:source-text": "Orrell C, Hagins DP, Belonosova E, et al. Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study. Lancet HIV. 2017; 4: e536-e546."
                    },
                    {
                        "ref-fulltext": "Zash R, Makhema J, Shapiro RL,. Neural-tube defects with dolutegravir treatment from the time of conception. N Engl J Med. 2018; 379: 979-981.",
                        "@id": "30",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Neural-tube defects with dolutegravir treatment from the time of conception"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85053199994",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "379"},
                                "pagerange": {
                                    "@first": "979",
                                    "@last": "981"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "R.",
                                    "@_fa": "true",
                                    "ce:surname": "Zash",
                                    "ce:indexed-name": "Zash R."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "J.",
                                    "@_fa": "true",
                                    "ce:surname": "Makhema",
                                    "ce:indexed-name": "Makhema J."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "R.L.",
                                    "@_fa": "true",
                                    "ce:surname": "Shapiro",
                                    "ce:indexed-name": "Shapiro R.L."
                                }
                            ]},
                            "ref-sourcetitle": "N Engl J Med."
                        },
                        "ce:source-text": "Zash R, Makhema J, Shapiro RL,. Neural-tube defects with dolutegravir treatment from the time of conception. N Engl J Med. 2018; 379: 979-981."
                    },
                    {
                        "ref-fulltext": "World Health Organization. Statement on DTG-Geneva 18 May 2018: potential safety issue affecting women living with HIV using dolutegravir at the time of conception. Available at: www.who.int/medicines/publications/./Statement-on-DTG-18May-2018final.pdf. Accessed October 16, 2018.",
                        "@id": "31",
                        "ref-info": {
                            "ref-website": {"ce:e-address": {
                                "$": "www.who.int/medicines/publications/./Statement_on_DTG_18May_2018final.pdf",
                                "@type": "email"
                            }},
                            "refd-itemidlist": {"itemid": {
                                "$": "85079956184",
                                "@idtype": "SGR"
                            }},
                            "ref-text": "Accessed October 16, 2018",
                            "ref-authors": {"collaboration": {
                                "@seq": "1",
                                "ce:text": "World Health Organization",
                                "ce:indexed-name": "World Health Organization"
                            }},
                            "ref-sourcetitle": "Statement on Dtg - Geneva 18 May 2018: Potential Safety Issue Affecting Women Living with Hiv Using Dolutegravir at the Time of Conception"
                        },
                        "ce:source-text": "World Health Organization. Statement on DTG-Geneva 18 May 2018: potential safety issue affecting women living with HIV using dolutegravir at the time of conception. Available at: www.who.int/medicines/publications/./Statement-on-DTG-18May-2018final.pdf. Accessed October 16, 2018."
                    },
                    {
                        "ref-fulltext": "European Medicines Agency. Press Release: new study suggests risk of birth defects in babies born to women on HIV medicine dolutegravir. 2018. Available at: https://www.ema.europa.eu/en/news/new-study-suggests-risk-birth-defects-babies-born-women-hiv-medicine-dolutegravir. Accessed October 16, 2018.",
                        "@id": "32",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://www.ema.europa.eu/en/news/new-study-suggests-risk-birth-defects-babies-born-women-hiv-medicine-dolutegravir",
                                "@type": "email"
                            }},
                            "refd-itemidlist": {"itemid": {
                                "$": "85063985851",
                                "@idtype": "SGR"
                            }},
                            "ref-text": "Accessed October 16, 2018",
                            "ref-authors": {"collaboration": {
                                "@seq": "1",
                                "ce:text": "European Medicines Agency",
                                "ce:indexed-name": "European Medicines Agency"
                            }},
                            "ref-sourcetitle": "Press Release: New Study Suggests Risk of Birth Defects in Babies Born to Women on Hiv Medicine Dolutegravir"
                        },
                        "ce:source-text": "European Medicines Agency. Press Release: new study suggests risk of birth defects in babies born to women on HIV medicine dolutegravir. 2018. Available at: https://www.ema.europa.eu/en/news/new-study-suggests-risk-birth-defects-babies-born-women-hiv-medicine-dolutegravir. Accessed October 16, 2018."
                    }
                ]
            }}
        }
    },
    "affiliation": [
        {
            "affiliation-city": "Kampala",
            "@id": "60071691",
            "affilname": "Joint Clinical Research Center Uganda",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60071691",
            "affiliation-country": "Uganda"
        },
        {
            "affiliation-city": "Moscow",
            "@id": "60069625",
            "affilname": "Ministry of Health of Russian Federation",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60069625",
            "affiliation-country": "Russian Federation"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Macon",
            "@id": "60026005",
            "affilname": "Mercer University School of Medicine",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60026005",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Khon Kaen",
            "@id": "60017165",
            "affilname": "Khon Kaen University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60017165",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Foster City",
            "@id": "60002909",
            "affilname": "Gilead Sciences Incorporated",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002909",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Chaing Mai",
            "@id": "60000881",
            "affilname": "Chiang Mai University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60000881",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Krasnoyarsk",
            "@id": "115403233",
            "affilname": "Krasnoyarsk Regional Center for Prevention and Control of AIDS",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/115403233",
            "affiliation-country": "Russian Federation"
        },
        {
            "affiliation-city": "Savannah",
            "@id": "113700425",
            "affilname": "Chatham Care Center",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/113700425",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Moscow",
            "@id": "108398532",
            "affilname": "Moscow Regional Center for the Prevention and Control of AIDS and Infectious Diseases",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/108398532",
            "affiliation-country": "Russian Federation"
        },
        {
            "affiliation-city": "Santo Domingo",
            "@id": "105310604",
            "affilname": "Instituto Dominicano de Estudios Virologicos (IDEV)",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/105310604",
            "affiliation-country": "Dominican Republic"
        },
        {
            "affiliation-city": "Orlando",
            "@id": "100429817",
            "affilname": "Orlando Immunology Center",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/100429817",
            "affiliation-country": "United States"
        }
    ],
    "coredata": {
        "srctype": "j",
        "eid": "2-s2.0-85073178758",
        "dc:description": "Background:Bictegravir, coformulated with emtricitabine/tenofovir alafenamide as a fixed-dose combination (B/F/TAF), is recommended for treatment of HIV-1-infection. Multiple studies of B/F/TAF in treatment-naive and virologically suppressed cohorts have shown high efficacy and tolerability with no treatment-emergent resistance through 48 weeks. Participants in these studies have been predominantly men. We report 48-week results from a phase 3 study evaluating switching to B/F/TAF, specifically in a globally distributed trial population of women.Methods:In this multicenter, randomized, open-label, active-controlled, noninferiority trial (ClinicalTrials.gov NCT02652624), women living with HIV who were virologically suppressed (HIV-1 RNA levels <50 copies/mL) on a regimen containing either TAF or tenofovir disoproxil fumarate were randomly assigned (1:1) to switch to B/F/TAF (50/200/25 mg) or stay on baseline regimen (SBR) once daily for 48 weeks. Primary endpoint was proportion of participants with plasma HIV-1 RNA ≥50 copies/mL at week 48 (U.S. Food and Drug Administration snapshot algorithm); prespecified noninferiority margin was 4%.Findings:We randomized 472 participants and treated 470 (234 B/F/TAF, 236 SBR). Switching to B/F/TAF was noninferior to SBR for the primary outcome, as 1.7% (4/234) vs 1.7% (4/236) had HIV-1 RNA ≥50 copies/mL at week 48 (difference 0.0%, 95.001% confidence interval: -2.9% to 2.9%). No individual receiving B/F/TAF developed treatment-emergent resistance. Both treatments were well-tolerated; no participant discontinued treatment because of an adverse event.Interpretation:Fixed-dose combination B/F/TAF provides a safe and efficacious option for ongoing treatment of HIV in women. This study contributes important data on safety, tolerability, and outcomes of antiretroviral therapy among women living with HIV.",
        "pubmed-id": "31609930",
        "prism:coverDate": "2019-11-01",
        "prism:aggregationType": "Journal",
        "prism:url": "https://api.elsevier.com/content/abstract/scopus_id/85073178758",
        "dc:creator": {"author": [{
            "ce:given-name": "Cissy",
            "preferred-name": {
                "ce:given-name": "Cissy",
                "ce:initials": "C.",
                "ce:surname": "Kityo",
                "ce:indexed-name": "Kityo C."
            },
            "@seq": "1",
            "ce:initials": "C.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60071691",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60071691"
            },
            "ce:degrees": "MD",
            "ce:surname": "Kityo",
            "@auid": "6602918610",
            "author-url": "https://api.elsevier.com/content/author/author_id/6602918610",
            "ce:indexed-name": "Kityo C."
        }]},
        "link": [
            {
                "@_fa": "true",
                "@rel": "self",
                "@href": "https://api.elsevier.com/content/abstract/scopus_id/85073178758"
            },
            {
                "@_fa": "true",
                "@rel": "scopus",
                "@href": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85073178758&origin=inward"
            },
            {
                "@_fa": "true",
                "@rel": "scopus-citedby",
                "@href": "https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85073178758&origin=inward"
            }
        ],
        "source-id": "15300154823",
        "citedby-count": "26",
        "prism:volume": "82",
        "subtype": "ar",
        "dc:title": "Switching to Fixed-Dose Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed HIV-1 Infected Women: A Randomized, Open-Label, Multicenter, Active-Controlled, Phase 3, Noninferiority Trial",
        "openaccess": "0",
        "prism:issn": "10779450 15254135",
        "publishercopyright": "© 2019 Wolters Kluwer Health, Inc. All rights reserved.",
        "prism:issueIdentifier": "3",
        "subtypeDescription": "Article",
        "prism:publicationName": "Journal of Acquired Immune Deficiency Syndromes",
        "prism:pageRange": "321-328",
        "prism:endingPage": "328",
        "openaccessFlag": "false",
        "prism:doi": "10.1097/QAI.0000000000002137",
        "prism:startingPage": "321",
        "dc:identifier": "SCOPUS_ID:85073178758",
        "dc:publisher": "Lippincott Williams and Wilkinskathiest.clai@apta.org"
    },
    "idxterms": {"mainterm": [
        {
            "$": "Adenine",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Adult",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Anti-HIV Agents",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "CD4 Lymphocyte Count",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Emtricitabine",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Female",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Heterocyclic Compounds, 4 or More Rings",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "HIV Infections",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "HIV-1",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Humans",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Male",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Middle Aged",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Tenofovir",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Treatment Outcome",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Young Adult",
            "@weight": "b",
            "@candidate": "n"
        }
    ]},
    "language": {"@xml:lang": "eng"},
    "authkeywords": {"author-keyword": [
        {
            "@_fa": "true",
            "$": "bictegravir"
        },
        {
            "@_fa": "true",
            "$": "HIV"
        },
        {
            "@_fa": "true",
            "$": "INSTI"
        },
        {
            "@_fa": "true",
            "$": "tenofovir alafenamide"
        },
        {
            "@_fa": "true",
            "$": "women"
        }
    ]},
    "subject-areas": {"subject-area": [
        {
            "@_fa": "true",
            "$": "Infectious Diseases",
            "@code": "2725",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Pharmacology (medical)",
            "@code": "2736",
            "@abbrev": "MEDI"
        }
    ]},
    "authors": {"author": [
        {
            "ce:given-name": "Cissy",
            "preferred-name": {
                "ce:given-name": "Cissy",
                "ce:initials": "C.",
                "ce:surname": "Kityo",
                "ce:indexed-name": "Kityo C."
            },
            "@seq": "1",
            "ce:initials": "C.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60071691",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60071691"
            },
            "ce:degrees": "MD",
            "ce:surname": "Kityo",
            "@auid": "6602918610",
            "author-url": "https://api.elsevier.com/content/author/author_id/6602918610",
            "ce:indexed-name": "Kityo C."
        },
        {
            "ce:given-name": "Debbie",
            "preferred-name": {
                "ce:given-name": "Debbie",
                "ce:initials": "D.",
                "ce:surname": "Hagins",
                "ce:indexed-name": "Hagins D."
            },
            "@seq": "2",
            "ce:initials": "D.",
            "@_fa": "true",
            "affiliation": {
                "@id": "113700425",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/113700425"
            },
            "ce:degrees": "MD",
            "ce:surname": "Hagins",
            "@auid": "36522862600",
            "author-url": "https://api.elsevier.com/content/author/author_id/36522862600",
            "ce:indexed-name": "Hagins D."
        },
        {
            "ce:given-name": "Ellen",
            "preferred-name": {
                "ce:given-name": "Ellen",
                "ce:initials": "E.",
                "ce:surname": "Koenig",
                "ce:indexed-name": "Koenig E."
            },
            "@seq": "3",
            "ce:initials": "E.",
            "@_fa": "true",
            "affiliation": {
                "@id": "105310604",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/105310604"
            },
            "ce:degrees": "MD",
            "ce:surname": "Koenig",
            "@auid": "7005320371",
            "author-url": "https://api.elsevier.com/content/author/author_id/7005320371",
            "ce:indexed-name": "Koenig E."
        },
        {
            "ce:given-name": "Anchalee",
            "preferred-name": {
                "ce:given-name": "Anchalee",
                "ce:initials": "A.",
                "ce:surname": "Avihingsanon",
                "ce:indexed-name": "Avihingsanon A."
            },
            "@seq": "4",
            "ce:initials": "A.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60028190",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190"
            },
            "ce:degrees": "MD",
            "ce:surname": "Avihingsanon",
            "@auid": "57196347321",
            "author-url": "https://api.elsevier.com/content/author/author_id/57196347321",
            "ce:indexed-name": "Avihingsanon A."
        },
        {
            "ce:given-name": "Ploenchan",
            "preferred-name": {
                "ce:given-name": "Ploenchan",
                "ce:initials": "P.",
                "ce:surname": "Chetchotisakd",
                "ce:indexed-name": "Chetchotisakd P."
            },
            "@seq": "5",
            "ce:initials": "P.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60017165",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60017165"
            },
            "ce:degrees": "MD",
            "ce:surname": "Chetchotisakd",
            "@auid": "56992885200",
            "author-url": "https://api.elsevier.com/content/author/author_id/56992885200",
            "ce:indexed-name": "Chetchotisakd P."
        },
        {
            "ce:given-name": "Khuanchai",
            "preferred-name": {
                "ce:given-name": "Khuanchai",
                "ce:initials": "K.",
                "ce:surname": "Supparatpinyo",
                "ce:indexed-name": "Supparatpinyo K."
            },
            "@seq": "6",
            "ce:initials": "K.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60000881",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60000881"
            },
            "ce:degrees": "MD",
            "ce:surname": "Supparatpinyo",
            "@auid": "6602542079",
            "author-url": "https://api.elsevier.com/content/author/author_id/6602542079",
            "ce:indexed-name": "Supparatpinyo K."
        },
        {
            "ce:given-name": "Natalya",
            "preferred-name": {
                "ce:given-name": "Natalya",
                "ce:initials": "N.",
                "ce:surname": "Gankina",
                "ce:indexed-name": "Gankina N."
            },
            "@seq": "7",
            "ce:initials": "N.",
            "@_fa": "true",
            "affiliation": {
                "@id": "115403233",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/115403233"
            },
            "ce:degrees": "MD",
            "ce:surname": "Gankina",
            "@auid": "57197827501",
            "author-url": "https://api.elsevier.com/content/author/author_id/57197827501",
            "ce:indexed-name": "Gankina N."
        },
        {
            "ce:given-name": "Vadim",
            "preferred-name": {
                "ce:given-name": "Vadim",
                "ce:initials": "V.",
                "ce:surname": "Pokrovsky",
                "ce:indexed-name": "Pokrovsky V."
            },
            "@seq": "8",
            "ce:initials": "V.",
            "@_fa": "true",
            "affiliation": {
                "@id": "108398532",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/108398532"
            },
            "ce:degrees": "MD",
            "ce:surname": "Pokrovsky",
            "@auid": "57215123636",
            "author-url": "https://api.elsevier.com/content/author/author_id/57215123636",
            "ce:indexed-name": "Pokrovsky V."
        },
        {
            "ce:given-name": "Evgeny",
            "preferred-name": {
                "ce:given-name": "Evgeny",
                "ce:initials": "E.",
                "ce:surname": "Voronin",
                "ce:indexed-name": "Voronin E."
            },
            "@seq": "9",
            "ce:initials": "E.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60069625",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60069625"
            },
            "ce:degrees": "MD",
            "ce:surname": "Voronin",
            "@auid": "7005899830",
            "author-url": "https://api.elsevier.com/content/author/author_id/7005899830",
            "ce:indexed-name": "Voronin E."
        },
        {
            "ce:given-name": "Jeffrey L.",
            "preferred-name": {
                "ce:given-name": "Jeffrey L.",
                "ce:initials": "J.L.",
                "ce:surname": "Stephens",
                "ce:indexed-name": "Stephens J.L."
            },
            "@seq": "10",
            "ce:initials": "J.L.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60026005",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60026005"
            },
            "ce:degrees": "MD",
            "ce:surname": "Stephens",
            "@auid": "57210456228",
            "author-url": "https://api.elsevier.com/content/author/author_id/57210456228",
            "ce:indexed-name": "Stephens J.L."
        },
        {
            "ce:given-name": "Edwin",
            "preferred-name": {
                "ce:given-name": "Edwin",
                "ce:initials": "E.",
                "ce:surname": "Dejesus",
                "ce:indexed-name": "Dejesus E."
            },
            "@seq": "11",
            "ce:initials": "E.",
            "@_fa": "true",
            "affiliation": {
                "@id": "100429817",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/100429817"
            },
            "ce:degrees": "MD",
            "ce:surname": "Dejesus",
            "@auid": "55549526100",
            "author-url": "https://api.elsevier.com/content/author/author_id/55549526100",
            "ce:indexed-name": "Dejesus E."
        },
        {
            "ce:given-name": "Hui",
            "preferred-name": {
                "ce:given-name": "Hui",
                "ce:initials": "H.",
                "ce:surname": "Wang",
                "ce:indexed-name": "Wang H."
            },
            "@seq": "12",
            "ce:initials": "H.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60002909",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002909"
            },
            "ce:degrees": "PhD",
            "ce:surname": "Wang",
            "@auid": "57196428615",
            "author-url": "https://api.elsevier.com/content/author/author_id/57196428615",
            "ce:indexed-name": "Wang H."
        },
        {
            "ce:given-name": "Rima K.",
            "preferred-name": {
                "ce:given-name": "Rima K.",
                "ce:initials": "R.K.",
                "ce:surname": "Acosta",
                "ce:indexed-name": "Acosta R.K."
            },
            "@seq": "13",
            "ce:initials": "R.K.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60002909",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002909"
            },
            "ce:degrees": "BS",
            "ce:surname": "Acosta",
            "@auid": "57205221636",
            "author-url": "https://api.elsevier.com/content/author/author_id/57205221636",
            "ce:indexed-name": "Acosta R.K."
        },
        {
            "ce:given-name": "Huyen",
            "preferred-name": {
                "ce:given-name": "Huyen",
                "ce:initials": "H.",
                "ce:surname": "Cao",
                "ce:indexed-name": "Cao H."
            },
            "@seq": "14",
            "ce:initials": "H.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60002909",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002909"
            },
            "ce:degrees": "MD",
            "ce:surname": "Cao",
            "@auid": "56471119200",
            "author-url": "https://api.elsevier.com/content/author/author_id/56471119200",
            "ce:indexed-name": "Cao H."
        },
        {
            "ce:given-name": "Erin",
            "preferred-name": {
                "ce:given-name": "Erin",
                "ce:initials": "E.",
                "ce:surname": "Quirk",
                "ce:indexed-name": "Quirk E."
            },
            "@seq": "15",
            "ce:initials": "E.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60002909",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002909"
            },
            "ce:degrees": "MD",
            "ce:surname": "Quirk",
            "@auid": "24282056300",
            "author-url": "https://api.elsevier.com/content/author/author_id/24282056300",
            "ce:indexed-name": "Quirk E."
        },
        {
            "ce:given-name": "Hal",
            "preferred-name": {
                "ce:given-name": "Hal",
                "ce:initials": "H.",
                "ce:surname": "Martin",
                "ce:indexed-name": "Martin H."
            },
            "@seq": "16",
            "ce:initials": "H.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60002909",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002909"
            },
            "ce:degrees": "MD",
            "ce:surname": "Martin",
            "@auid": "56173399700",
            "author-url": "https://api.elsevier.com/content/author/author_id/56173399700",
            "ce:indexed-name": "Martin H."
        },
        {
            "ce:given-name": "Tariro",
            "preferred-name": {
                "ce:given-name": "Tariro",
                "ce:initials": "T.",
                "ce:surname": "Makadzange",
                "ce:indexed-name": "Makadzange T."
            },
            "@seq": "17",
            "ce:initials": "T.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60002909",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002909"
            },
            "ce:degrees": "MD, PhD",
            "ce:surname": "Makadzange",
            "@auid": "6506062019",
            "author-url": "https://api.elsevier.com/content/author/author_id/6506062019",
            "ce:indexed-name": "Makadzange T."
        }
    ]}
}}